1. Intermittent ADT may improve quality of life in men with prostate cancer
Researchers at Laval University in Canada conducted a systematic review and meta-analysis comparing intermittent and continuous androgen deprivation therapy in patients with prostate cancer. Androgen deprivation is the standard therapy for patients with advanced or recurrent prostate cancer. However, this treatment causes adverse effects, alters quality of life, and may lead to castration-resistant disease. Intermittent androgen deprivation has been studied as an alternative
The review by Mangan et al. included the results of 15 trials from 22 articles published between 2000 and 2013. The authors observed no significant difference in overall survival between intermittent and continuous therapy. In addition there was no difference between the two treatment regimens in cancer-specific survival and progression-free survival. Only a minimal difference in patient’s self-reported quality of life was observed between the two treatment regimens, with an improvement in physical and sexual functioning with intermittent therapy. Overall the authors concluded that some quality of life criteria appeared to improve with intermittent therapy, and it can be considered as an alternative option in patients with recurrent or metastatic prostate cancer.